Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468223 | 1.00 | ALDH1A1 (0.32) | ALDH1A1CNR1CNR2TRPA1TRPV1 | |
| SCHEMBL5802298 | 1.00 | ALDH1A1 (0.32) | ALDH1A1CNR1CNR2TRPA1TRPV1 | |
| SCHEMBL16506576 | 0.83 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL16506578 | 0.83 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL28583659 | 0.77 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL1190808 | 0.75 | — | — | |
| SCHEMBL11388076 | 0.75 | — | — | |
| SCHEMBL11650382 | 0.75 | — | — | |
| SCHEMBL310856 | 0.74 | — | — | |
| SCHEMBL29000478 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 633 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888338-B2 | 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]decanes | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-02-15 | — | — | US | claimed |
| US-20060178350-A1 | 7-(2-Cyclohexylidene-ethylidene)-spiro[4.5]decanes | UNIVERSITEIT GENT (BE) | 2006-08-10 | — | — | US | claimed |
| WO-2006060884-A1 | 7-(2-CYCLOHEXYLIDENE-ETHYLIDENE)-SPIRO[4.5]DECANES | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2006-06-15 | — | — | WO | claimed |
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2024-07-16 | — | — | US | disclosed |
| US-12029728-B2 | Small molecules with anti-protozoan activity | NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4387608-A1 | PRODRUGS AND DERIVATIVES OF PSILOCIN AND USES THEREOF | Terran Biosciences, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4384498-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Onconova Therapeutics, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-118119389-A | Prodrugs and derivatives of des-phosphate nupharicin and uses thereof | 人类生物科学股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118103357-A | FABP4/5 inhibitors, methods of use and methods of preparation | 塞洛拉姆股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118076583-A | Methods and compositions for treating cancer | 安可诺瓦治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024107955-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ONCONOVA THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-1747204-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | The Procter and Gamble Company (US) | 2007-01-31 | — | — | EP | disclosed |
| EP-1737830-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | The Procter and Gamble Company (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060178350-A1 | 7-(2-Cyclohexylidene-ethylidene)-spiro[4.5]decanes | UNIVERSITEIT GENT (BE) | 2006-08-10 | — | — | US | disclosed |
| WO-2006060884-A1 | 7-(2-CYCLOHEXYLIDENE-ETHYLIDENE)-SPIRO[4.5]DECANES | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006060885-A1 | 7-(2-CYCLOHEXYLIDENE-ETHYLIDENE)-SPIRO[5.5]UNDECANES USEFUL FOR MAKING PHARMACEUTICAL COMPOSITIONS | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2006-06-15 | — | — | WO | disclosed |
| WO-2005105758-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005105757-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-03 | — | — | US | disclosed |
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | IL1B, IL1A, IL6 | ALDH1A1 455/4885CNR1 3414/4885CNR2 3733/4885 |
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | IL1B, IL1A, IL6 | ALDH1A1 455/4885CNR1 3414/4885CNR2 3733/4885 |
| US-20060178350-A1 | 7-(2-Cyclohexylidene-ethylidene)-spiro[4.5]decanes | NR3C2, PKD2, REN | ALDH1A1 59/4885CNR1 417/4885CNR2 176/4885 |
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | GPR119, GPR3, GPR39 | ALDH1A1 1111/4885CNR1 69/4885CNR2 40/4885 |
| US-12029728-B2 | Small molecules with anti-protozoan activity | GBA3, CTSA, ITPA | ALDH1A1 3187/4885CNR1 3192/4885CNR2 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.